| Objective:Ovarian cancer is the most common gynecologic malignancy in the world, the5year survival rate is30%-40%nowdays.And its morbidity and mortality rate ranks first in gynecological malignancies. Adoptive immunotherapy is increasingly becoming an important weapon in the cell therapy of ovarian cancer. Through this study, observe the changes of DC-CIK (dendritic cell-cytokine induced killer cell) adoptive immunotherapy to ovarian cancer patients’peripheral blood lymphocyte subsets and related cytokines, and evaluate the clinical efficacy of the DC-CIK cell immunotherapy to ovarian cancer.Methods:Select22ovarian cancer patients with the specific histopathological examination at the Second Hospital of Jilin University, tumor biological treatment center during March2010to March2013, and their peripheral blood mononuelear cells(PBMC) were isolated from these patients who had been treated with standard protocols, and assay accepted DC-CIK immunotherapy after different cycles using flow cytometry and enzyme-linked immunosorbent, and its peripheral blood lymphocyte subsets (T lymphocyte subsets (CD3+), helper T cell subsets (CD3+/CD4+), cytotoxic T cell subsets (CD3+/CD8+), NKT cell subsets (CD3+/CD16+56+)), and associated factors IL-2, TNF-α, IFN-γ expression levels are also assayed. Meanwhile allergies, blood system, cardiovascular system, liver, kidneys, gastrointestinal tract, systemic symptoms are monitored and evaluated for safety. And the datas were processed by the software of SPSS13.0.Result:1.Compared with before treatment, DC-CIK cell-mediated immunity in patients treated with peripheral blood T lymphocyte subsets have no significant change at four cycles and7cycles, that is, T lymphocyte subsets (CD3+), helper T cell subsets (CD3+/CD4+), cytotoxic T cell subsets (CD3+/CD8+), NKT cell subsets (CD3+/CD16+56+) increased slightly compared with before treatment, but there was no significant statistical difference2.IL-2, TNF-α, IFN-γ levels have advanced compared with before treatment at four cycles, but the difference was not significant, and at the seven cycles, IL-2, TNF-α, IFN-γ levels have advanced than before treatment significantly and there is a significant difference (P<0.05);3.After DC-CIK cells adoptive immunotherapy, physical and emotional function of the the patients have been improved significantly than before treatment.4.Patients showed good tolerability in the treatment of a total of154cycles, and the incidence of fever, urticaria, palpitation and liver damage has a lower incidence.Conclusion:1.DC-CIK cell immunotherapy can significantly improve the immune status of patients with ovarian cancer and improve the ability of anti-tumor.2.There is no significant adverse reactions in clinical application, so it can be used as an important means of adjuvant therapy to patients with ovarian cancer. |
PDF Full Text Request